Loading...

Home
ETF
TVGNW

TVGNW

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

TVGNW News

TEVOGEN MEETS NASDAQ'S MINIMUM BID PRICE CRITERIA AGAIN

TEVOGEN BIO HOLDINGS INC - BOARD IS STILL ASSESSING POSSIBLE ONE-TIME SPECIAL CASH DIVIDEND

Mar 13 2026moomoo

TEVOGEN BIO HOLDINGS - PRIMARY INVESTOR AFFIRMS PLAN TO KEEP EXISTING SHAREHOLDINGS

Mar 13 2026moomoo

TEVOGEN.AI ANNOUNCES PROGRESS IN PREDICTCELL™ BETA, SHOWCASING ENHANCED ACCURACY METRICS AND GROWING ITS PROPRIETARY AI FRAMEWORK

Mar 13 2026moomoo

TEVOGEN BIO HOLDINGS INC - AGREEMENT MAY TRANSFORM TEVOGEN INTO A PROFITABLE HEALTHCARE BUSINESS

Feb 26 2026moomoo

TEVOGEN ENTERS LETTER OF INTENT TO ASSESS POSSIBLE ACQUISITION OF SCIOMETRIX AND ITS DIGITAL CARE MANAGEMENT PLATFORM, CLINICUS

Feb 26 2026moomoo

TEVOGEN BOARD CONSIDERS POSSIBLE ONE-TIME SPECIAL CASH DIVIDEND FOR SHAREHOLDERS

Jan 30 2026moomoo

Tevogen Addresses Financial Report, Emphasizing Robust Capital Efficiency and Minimal Cash Burn

Nov 03 2025Newsfilter

Tevogen Executives Connect with Business and Community Leaders to Showcase Recent Achievements

Oct 29 2025Newsfilter

Tevogen Provides Update on TVGN 489 Amid Increasing Interest from Long COVID Patients

Oct 15 2025Newsfilter

Tevogen Achieves Significant Progress in AI Efforts to Improve T Cell–Based Therapies with 100x Expansion of PredicTcell™ Beta Data

Sep 25 2025Newsfilter

Tevogen Praises HHS for Tackling Long COVID, Highlights TVGN 489's Potential Benefits for 20 Million Americans

Sep 19 2025Newsfilter

Tevogen's CIO and Head of Tevogen.AI, Mittul Mehta, to Participate in Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 10 2025Newsfilter

Tevogen Projects Approximately $6.5 Billion in Revenue Over 5 Years for Liver Cancer Prevention Product Targeting High-Risk Chronic Hepatitis B Patients

Sep 09 2025Newsfilter

Tevogen Reveals Valuation of Essential Assets and Future Projections for Pipeline Products Targeting EBV-Related Leukemia and Lymphomas

Sep 04 2025Newsfilter

Tevogen Highlights the Significance of Targeted Immunotherapies, Such as TVGN 489, for At-Risk Individuals Infected with SARS-CoV-2

Sep 03 2025Newsfilter